A TOPPING-OUT ceremony took place at a new £19million cancer research facility based at Glasgow University’s Garscube Estate, Bearsden, last Thursday.
The main contractor, Mansell, also handed over a cheque for £1,000 to the Beatson Pebble Appeal - which they had raised by holding various events throughout the year.
When finished in autumn 2012, this pioneering new centre will help scientists in Glasgow convert groundbreaking discoveries into real benefits for cancer patients.
The Beatson Translational Research Centre (TRC) is the third and final phase of a new co-ordinated research hub that places Glasgow at the forefront of cancer research in the UK.
The TRC will work alongside existing facilities such as the Beatson Institute in Glasgow which carries out basic scientific research and those providing clinical care of cancer patients at the Beatson West of Scotland Cancer Centre at Gartnavel.
Professor Neal Juster, vice-principal of the University of Glasgow, said: “This new facility will complete one of the biggest centres for cancer research in the UK and will play a major part in the development of new treatments for a range of the most common cancers.
“This will provide unparalleled resources for teaching and research at the University of Glasgow and will cement our place at the forefront of cancer research in the UK.”
The Beatson TRC aims to deliver real improvements in patients’ lives and speed up the process of drug discovery.
It will specialise in the common tumours and those that cause the most deaths in Scotland such as endocrine (breast, prostate and ovarian), smoking related (lung, throat, oral) or gastro intestinal.
It will support over 400 cancer specialists and world-class basic and clinical researchers as well as offer world-leading facilities for over 60 per cent of the Scottish population. The centre also creates unparalleled opportunities for cross-disciplinary research in the fight against cancer.
Callum Leslie, regional director Mansell, said: “We are delighted to be involved in the construction of this world-class building and helping to create a facility that will ultimately provide huge benefits in the treatment of cancer. This is something that as a company based in the West of Scotland our staff and workforce identify with on a personal level.”